- Home
- A-Z Publications
- Current Pharmaceutical Biotechnology
- Previous Issues
- Volume 15, Issue 9, 2014
Current Pharmaceutical Biotechnology - Volume 15, Issue 9, 2014
Volume 15, Issue 9, 2014
-
-
An Oligodeoxynucleotide with CCT Repeats Restrains CpG ODN-Induced TLR9 Trafficking
Authors: Xiaoling Zhang, Wei Sun, Xiuli Wu, Hua Wang, Youyou Yan, Sheng Guo, Dandan Song, Hainan Li, Shuang Gao, Luowei Wang, Yongli Yu and Liying WangToll-like receptor 9 (TLR9) can sense pathogen DNA and CpG ODN or even self-DNA by trafficking assisted by Unc93B1, an endoplasmic reticulum (ER) transmembrane protein, from ER to endolysosomes or cell surface. In previous study, we found that an oligodeoxynucleotide with CCT repeats (SAT05f) could selectively inhibit TLR7/9 activation. However, the mechanism for the inhibitory activity of SAT05f is still unknown. In pres Read More
-
-
-
Co-delivery of Plasmid DNA and Antisense Oligodeoxyribonucleotide into Human Carcinoma Cells by Cationic Liposomes
This study aimed to evaluate the co-delivery of cationic liposome/plasmid DNA complexes and cationic liposome/antisense oligodeoxyribonucleotide (AS ODN) complexes in HeLa human cervical carcinoma cells. Dimethyldioctadecyl ammonium bromide (DDAB): dioleoyl phosphatidylethanolamine (DOPE) liposome/plasmid DNA complexes, and DDAB:DOPE liposome/AS ODN complexes were formulated and characterized in terms of Read More
-
-
-
Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Incorporating Fatty Acid-Modified Polyethylenimine
Authors: Zhihua Guo, Yujing Li, Yige Fu, Tianqi Guo, Xin Li, Shuang Yang and Jing XieAntisense oligonucleotides (ASOs) have promising therapeutic potential in oncotherapy. However, low stability and efficacy limit their application in the clinic. Cationic liposomes have been investigated as delivery vehicles for ASOs. Here, we report the synthesis and evaluation of an ASO delivery vehicle comprising cationic liposomes incorporating fatty acid-modified polyethylenimine. An oleic acid derivative of branched polyethyl Read More
-
-
-
Enhancing Nucleic Acid Delivery, Insights from the Cationic Phospholipid Carriers
Authors: Rumiana Koynova and Boris TenchovThe development of nucleic acid-based drugs has attracted considerable interest in the past two decades as a new category of biologics. A key challenge in successfully achieving the full potential of nucleotide therapeutics is their efficient delivery. Synthetic cationic lipids are currently the most extensively used non-viral nucleotide carriers because of their ability to form complexes with the nucleic acids. Here we examine t Read More
-
-
-
Mechanism of A pH-induced Peptide Inserting into a POPC Bilayer: A Molecular Dynamic Study
Authors: Chui-Peng Kong, Ying-Lu Cui, Ji-Long Zhang, Qing-Chuan Zheng and Hong-Xing ZhangMembrane insertion peptides have been developed in recent years and serve as cargos to deliver small molecules into cells. A class of membrane insertion peptides is the so called pH-induced peptides (pHLIPs), which are able to insert into membrane when the environment pH is acidic. Despite a number of experimental studies, the insertion process as well as the penetration mechanism is still worth study with computational me Read More
-
-
-
Microfluidic Assembly of Lipid Nanoparticles for Delivery of Antisense Oligonucleotides
Authors: Yulin Zhou, Zhaoli Meng, Tianqi Guo, Yige Fu, Robert J. Lee and Jing XieMicrofluidically (MF) synthesized lipid nanoparticles (LNPs) for antisense oligonucleotides (ODN) delivery have been shown to be superior to those prepared by bulk mixing (BM). In this study, a 5-inlet MF chip was used to synthesize LNPs loaded with LOR-2501, an antisense ODN targeting the ribonucleotide reductase R1 subunit. The size distribution of ODN- LNPs was measured by dynamic light scattering. The cytotoxicity of O Read More
-
-
-
Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives
Authors: Chenguang Zhou, Zhaogang Yang and Lesheng TengNanoparticles have shown great promise for improving the efficacy of nucleic acid drugs that lack permeability and bioavailability needed for reaching their intracellular site of action. The pharmacokinetics of the nucleic acid nanomedicines contributes greatly to their pharmacodynamic and toxicity characteristics. The pharmacokinetics of nanomedicines is determined by their physiochemical properties, such as particle s Read More
-
-
-
Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Authors: Xinmei Wang, Xiaomeng Huang, Zhaogang Yang, Daniel Gallego-Perez, Junyu Ma, Xi Zhao, Jing Xie, Ichiro Nakano and L. J. LeeObjective: Among heterogeneous glioblastoma multiforme (GBM) cells, glioblastoma stem cells (GSCs) is a subpopulation having a critical role in tumor initiation and therapy resistance. Thus targeting GSCs would be an essential step to completely eradicate this lethal disease. MicroRNA-1 (miR-1) expression is deregulated in GBM patients and restoration of miR-1 by viral-vector in GBM cells has been demonstrated to inhibit Read More
-
-
-
Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery
Authors: Raquel Petrilli, Josimar O. Eloy, Juliana M. Marchetti, Renata F.V. Lopez and Robert J. LeeAntisense oligonucleotides (AS-ODNs) are short, single-stranded DNA molecules designed to bind specifically to a target messenger RNA (mRNA) and down-regulate gene expression. Despite being a promising class of therapeutics for a variety of diseases, they face major hurdles limiting their clinical application, including low intracellular delivery and poor in vivo stability. Among strategies available to enhance delivery, lipid nan Read More
-
-
-
The Effects of Fusion Structure on the Expression and Bioactivity of Human Brain Natriuretic Peptide (BNP) Albumin Fusion Proteins
More LessHuman brain natriuretic peptide (BNP) is utilized in the treatment of acute decompensated congestive heart failure. However, BNP has limited clinical use owing to its rapid clearance and the need for continuous intravenous infusion. Thus, we generated human serum albumin (HSA)-BNP fusion constructs to produce long-acting fusion proteins in Pichia pastoris. Four fusion proteins, BNP–HSA, (BNP)2–HSA, (BNP)4–HSA, and Read More
-
-
-
Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Recent advances in nanotechnology and nanobiotechnology have contributed to the development of nanomaterials, able to be used as drug carriers, probes, targets or cytostatic drugs by itself. Nanomedicine is now the leading area in nanotechnology where a large number and types of nanoparticles (NPs) has been developed and several are already in the clinical practice. Chemotherapy is one of the most widely used st Read More
-
-
-
Use of the Amide II Infrared Band of Proteins for Secondary Structure Determination and Comparability of Higher Order Structure
Authors: Brian M. Murphy, Jennifer D'Antonio, Mark C. Manning and Wasfi Al-AzzamDemonstrating comparability of secondary structure composition as part of higher order structure (HOS) in therapeutic proteins is a significant challenge. Previously, we showed that the variability of second derivative amide I Fourier transform infrared (FTIR) spectra were small enough that significant differences in secondary structures could be seen for a variety of model proteins. Those comparisons used spectral overlap a Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cpb
Journal
10
5
false
en
